NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation today welcomed the publication of an article
in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS
clinical trial, which evaluates the Company's second-generation
TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The
article in the April 24 edition of JACC concluded that the shorter
procedure time and lower bailout rate of the TAXUS Liberte Stent
system compared to the TAXUS(R) Express2(TM) Stent system may
represent a clinical surrogate for the improved deliverability and
conformability of the TAXUS Liberte Stent as compared to the TAXUS
Express Stent.

TAXUS ATLAS is a global, multi-center single arm trial comparing
the TAXUS Liberte paclitaxel-eluting stent system to a case-matched
control group of patients from the TAXUS IV and TAXUS V de novo
studies that received the TAXUS Express2 paclitaxel-eluting stent
system. Even with more complex lesion characteristics(2) compared
to the control group, the TAXUS ATLAS trial met its primary
endpoint of nine-month target vessel revascularization (TVR)
non-inferiority.

The TAXUS ATLAS nine-month results also support safety, as
demonstrated by low rates of Major Adverse Cardiac Events (MACE)
and stent thrombosis. The MACE rate and its components, including
cardiac death, myocardial infarction and TVR, were comparable to
control despite the higher percentage of complex lesions for the
TAXUS Liberte Stent arm. Cardiac death for the control group was
0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent
(p=1.00). Myocardial infarction was 3.9 percent for the control
group compared to 3.7 percent for the TAXUS Liberte Stent
(p=0.9030). The nine-month TVR rate for the control group was 7.1
percent compared to 8.0 percent for the TAXUS Liberte Stent
(p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte
Stent group, as compared to 8.9 perc
ent for the control group
(p=0.83) were maintained at 12 months. In addition, nine-month
stent thrombosis rates for both groups were low and similar for the
TAXUS Liberte Stent (0.8 percent) and control stent (0.7 percent,
p=1.0).

"ATLAS clinical outcomes highlight that despite more complex
lesions, the TAXUS Liberte Stent performed extremely well and
achieved similar rates of death, myocardial infarction and repeat
procedures compared to an historical TAXUS Express control," said
Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac
and Vascular Research, Washington Adventist Hospital, Takoma Park,
Maryland, and co-principal investigator of the TAXUS ATLAS
trial.

Data reported in the JACC article showed the TAXUS Liberte Stent
was associated with significantly shorter procedural times. The
study documented shorter average procedure times of 47.8 minutes
for TAXUS Liberte Stent versus 53.0 minutes in the control arm
(p=0.0052). The need to use additional stents due to procedural
complications was reduced by nearly 50 percent in the TAXUS Liberte
Stent group (3.1 percent) versus control (6.0 percent)
(p=0.0038).

"The TAXUS Liberte Stent represents the latest innovation of our
drug-eluting stent pipeline and we are pleased that the TAXUS ATLAS
results confirm its positive performance," said Paul LaViolette,
Chief Operating Officer of Boston Scientific. "It is also further
testament to the leadership of Boston Scientific that we are able
to take a proven drug like paclitaxel and successfully transition
it to an even more deliverable platform such as the Liberte
Stent."

The Company received the CE Mark for the TAXUS Liberte stent in
Europe and other international markets in September 2005, and it is
currently the market-leading drug-eluting stent outside the United
States. The TAXUS Liberte stent is currently pending approval by
the U.S. Food and Drug Administration and is not available for sale
in the United States.

Boston
Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more information,
please visit: http://www.bostonscientific.com
.

This press release contains forward-looking statements. Boston
Scientific wishes to caution the reader of this press release that
actual results may differ from those discussed in the
forward-looking statements and may be adversely affected by, among
other things, risks associated with product development and
commercialization, clinical trials, intellectual property,
regulatory approvals, competitive offerings, Boston Scientific's
overall business strategy, and other factors described in Boston
Scientific's filings with the Securities and Exchange
Commission.

(Date:12/8/2016)... Information products and services provider Elsevier has launched ... largest abstract and citation database of peer-reviewed literature, providing the scholarly ... publishers. The new set of metrics will improve decisions on where ... a journal,s editorial strategy. ... , CiteScore metrics comprise a ...

(Date:12/8/2016)... 2016 Dignitana, a world leader in medical ... Technology, creator of the award-winning, patented Boa® system, to ... the DigniCap® scalp cooling system. DigniCap® was cleared by ... and is the first medical scalp cooling device to ... system features a patented tight-fitting silicone cooling cap that ...

(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...

(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...